SVB Securities analyst Thomas Smith downgraded Axcella Health to Market Perform from Outperform with a price target of $2, down from $6, after the company discontinuing its ongoing Phase 2b trial of AXA1125 in nonalcoholic steatohepatitis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXLA: